Vigilare Wealth Management trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 4.5% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 12,231 shares of the company’s stock after selling 572 shares during the period. Johnson & Johnson makes up approximately 1.9% of Vigilare Wealth Management’s holdings, making the stock its 15th largest position. Vigilare Wealth Management’s holdings in Johnson & Johnson were worth $1,821,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Winslow Evans & Crocker Inc. raised its holdings in Johnson & Johnson by 0.3% in the 2nd quarter. Winslow Evans & Crocker Inc. now owns 21,603 shares of the company’s stock worth $3,037,000 after acquiring an additional 69 shares during the last quarter. Lathrop Investment Management Corp raised its holdings in Johnson & Johnson by 1.4% in the 2nd quarter. Lathrop Investment Management Corp now owns 4,901 shares of the company’s stock worth $689,000 after acquiring an additional 69 shares during the last quarter. Reik & CO. LLC raised its holdings in Johnson & Johnson by 0.4% in the 2nd quarter. Reik & CO. LLC now owns 17,727 shares of the company’s stock worth $2,493,000 after acquiring an additional 70 shares during the last quarter. Old North State Trust LLC raised its holdings in Johnson & Johnson by 0.5% in the 2nd quarter. Old North State Trust LLC now owns 13,666 shares of the company’s stock worth $1,922,000 after acquiring an additional 71 shares during the last quarter. Finally, Delta Investment Management LLC raised its holdings in Johnson & Johnson by 1.0% in the 2nd quarter. Delta Investment Management LLC now owns 7,406 shares of the company’s stock worth $1,041,000 after acquiring an additional 71 shares during the last quarter. Institutional investors own 67.44% of the company’s stock.

A number of equities research analysts have commented on JNJ shares. Stifel Nicolaus downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Wednesday, August 19th. SVB Leerink reaffirmed an “outperform” rating on shares of Johnson & Johnson in a research report on Wednesday, July 15th. Citigroup lifted their target price on shares of Johnson & Johnson from $165.00 to $170.00 and gave the stock a “buy” rating in a research report on Friday, July 17th. Raymond James lifted their target price on shares of Johnson & Johnson from $157.00 to $158.00 and gave the stock an “outperform” rating in a research report on Friday, July 17th. Finally, Zacks Investment Research downgraded shares of Johnson & Johnson from a “hold” rating to a “sell” rating and set a $150.00 target price for the company. in a research report on Tuesday, July 7th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and ten have given a buy rating to the company. Johnson & Johnson has a consensus rating of “Buy” and a consensus price target of $164.93.

In other Johnson & Johnson news, EVP Ashley Mcevoy sold 29,000 shares of the business’s stock in a transaction on Tuesday, July 28th. The shares were sold at an average price of $147.47, for a total value of $4,276,630.00. Following the sale, the executive vice president now owns 21,682 shares in the company, valued at approximately $3,197,444.54. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Kathryn E. Wengel sold 16,115 shares of the business’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $153.52, for a total transaction of $2,473,974.80. Following the completion of the sale, the executive vice president now owns 66,658 shares in the company, valued at approximately $10,233,336.16. The disclosure for this sale can be found here. Corporate insiders own 0.27% of the company’s stock.

Shares of Johnson & Johnson stock opened at $148.10 on Friday. The company has a market capitalization of $389.92 billion, a P/E ratio of 23.29, a P/E/G ratio of 3.36 and a beta of 0.68. The company has a debt-to-equity ratio of 0.40, a quick ratio of 0.99 and a current ratio of 1.25. The company has a fifty day moving average of $148.57 and a 200 day moving average of $146.59. Johnson & Johnson has a fifty-two week low of $109.16 and a fifty-two week high of $157.00.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Sunday, October 18th. The company reported $2.20 earnings per share for the quarter, topping the consensus estimate of $1.98 by $0.22. The company had revenue of $21.08 billion during the quarter, compared to the consensus estimate of $20.15 billion. Johnson & Johnson had a net margin of 22.69% and a return on equity of 35.21%. Johnson & Johnson’s quarterly revenue was up 1.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.12 EPS. Analysts forecast that Johnson & Johnson will post 8 EPS for the current year.

Johnson & Johnson Profile

Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.

See Also: What are earnings reports?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.